Promoted by the manufacturer of nalmefene, the bill would require any standing order for an opioid overdose reversal drug to allow an individual to choose any FDA-approved such drug or formulation.

MDDCSAM testimony reviews some possible unintended consequences, and possibly false assumptions about naloxone.